文献速递胸部肿瘤放疗放疗物理与技术

整合治疗前后CT评估的生存风险指标可改善早期非小细胞肺癌立体定向放疗患者的风险分层

Integration of Risk Survival Measures Estimated From Pre- and Posttreatment Computed Tomography Scans Improves Stratification of Patients With Early-Stage Non-small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy.
PubMed 文献 · Int J Radiat Oncol Biol Phys · 2021-01-19

该研究开发了一个影像组学模型,整合治疗前和治疗后CT扫描估计的死亡风险及变化,用于预测接受立体定向体部放疗(SBRT)的早期非小细胞肺癌(ES-NSCLC)患者的总生存。模型在验证队列中预测生存的c-index最高达0.734,并可将患者分为4个生存差异显著的亚组。

要点

  • 治疗前后CT影像组学风险整合可改善SBRT后ES-NSCLC患者生存分层。
  • 验证队列预测生存的c-index最高达0.734。

核心结论

  • 整合治疗前后CT扫描估计的生存风险指标有助于区分SBRT后预期生存良好与较差的患者。
  • 基于影像组学的纵向风险分析可能有助于识别可从SBRT后辅助治疗(如免疫治疗)中获益的早期NSCLC患者。

研究设计与样本

  • 研究纳入两个均接受SBRT(中位剂量50 Gy,4-5次)治疗的ES-NSCLC队列。
  • 在100例有治疗计划CT的发现队列中构建预测模型,并在60例有治疗前后CT的独立验证队列中评估性能。

主要发现

  • 预测模型在验证队列中预测生存结局的c-index最高达0.734。

关键数值与推荐

  • SBRT中位剂量为50 Gy,分4-5次。
  • 验证队列预测生存的c-index最高为0.734。

临床怎么用

  • 可利用治疗前和治疗后CT的影像组学风险指标对SBRT后ES-NSCLC患者进行生存分层。
  • 纵向风险变化分析可能辅助筛选SBRT后适合辅助治疗(如免疫治疗)的患者。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: To predict overall survival of patients receiving stereotactic body radiation therapy (SBRT) for early-stage non-small cell lung cancer (ES-NSCLC), we developed a radiomic model that integrates risk of death estimates and changes based on pre- and posttreatment computed tomography (CT) scans. We hypothesize this innovation will improve our ability to stratify patients into various oncologic outcomes with greater accuracy. METHODS AND MATERIALS: Two cohorts of patients with ES-NSCLC uniformly treated with SBRT (a median dose of 50 Gy in 4-5 fractions) were studied. Prediction models were built on a discovery cohort of 100 patients with treatment planning CT scans, and then were applied to a separate validation cohort of 60 patients with pre- and posttreatment CT scans for evaluating their performance. RESULTS: Prediction models achieved a c-index up to 0.734 in predicting survival outcomes of the validation cohort. The integration of the pretreatment risk of survival measures (risk-high vs risk-low) and changes (risk-increase vs risk-decrease) in risk of survival measures between the pretreatment and posttreatment scans further stratified the patients into 4 subgroups (risk: high, increase; risk: high, decrease; risk: low, increase; risk: low, decrease) with significant difference (χ2 = 18.549, P = .0003, log-rank test). There was also a significant difference between the risk-increase and risk-decrease groups (χ2 = 6.80, P = .0091, log-rank test). In addition, a significant difference (χ2 = 7.493, P = .0062, log-rank test) was observed between the risk-high and risk-low groups obtained based on the pretreatment risk of survival measures. CONCLUSION: The integration of risk of survival measures estimated from pre- and posttreatment CT scans can help differentiate patients with good expected survival from those who will do more poorly following SBRT. The analysis of these radiomics-based longitudinal risk measures may help identify patients with early-stage NSCLC who will benefit from adjuvant treatment after lung SBRT, such as immunotherapy.

来源:Int J Radiat Oncol Biol Phys,查看原文。版权归原作者所有。

引用

  1. Jiao Z, Li H, Xiao Y, et al. Integration of Risk Survival Measures Estimated From Pre- and Posttreatment Computed Tomography Scans Improves Stratification of Patients With Early-Stage Non-small Cell Lung Cancer Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys. 2021. PMID: 33333202. doi:10.1016/j.ijrobp.2020.12.014

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。